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with 48.6% (n = 31,717) and 50.0% (n = 32,614) for the
50-mg and 100-mg doses, respectively. Ninety-four
percent of prescriptions were ﬁlled with six tablets, and
only 2% of prescriptions (n = 1309) exceeded the quan-
tity vs. time limit. Members paid an average copay of $13
per prescription. CONCLUSIONS: This estimate of
PMPM cost falls within the range previously reported in
the literature. In comparison with PMPM costs reported
for other drug classes, such as proton pump inhibitors or
cyclooxygenase-2 inhibitors, the amount spent on silde-
naﬁl citrate is considerably lower and of lesser concern to
the pharmacy budget.
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OBJECTIVES: Managed care organizations (MCOs)
have traditionally used various types of formulary access
to control cost, with varied success. In this case study, we
determined the actual economic impact of adding silde-
naﬁl citrate to the formulary of a large national MCO by
types of access status. METHODS: Claims data for silde-
naﬁl prescriptions were analyzed for the 12-month period
from August 2001 through July 2002 for this MCO 
and for 7 of its regional areas. Per member per month
(PMPM) costs of sildenaﬁl coverage were calculated by
various formulary status at both the regional and national
levels. RESULTS: The MCO did not require prior autho-
rization for sildenaﬁl prescriptions but did impose restric-
tions on the number of sildenaﬁl tablets per monthly
prescription cycle. The MCO used open, closed, and
incented formularies to control access to sildenaﬁl. Mean
number of sildenaﬁl tablets/month varied from 4.9 to 
6.7 tablets. PMPM costs of sildenaﬁl coverage for the
regional areas were $0.07, $0.11, $0.11, $0.14, $0.15,
$0.15, and $0.18. Type of formulary did not fully explain
variance in costs between regions. In 5 of the 7 areas in
which most patients were covered under an incented for-
mulary, PMPM costs of sildenaﬁl coverage ranged from
$0.11 to $0.15. In the 2 regions with the greatest per-
centage of patients covered under a closed formulary
plan, PMPM costs of sildenaﬁl coverage were $0.07
(44% closed) and $0.15 (54% closed). Whereas in the 3
regions with the most patients covered under an open for-
mulary, PMPM costs of sildenaﬁl coverage were $0.11
(27% open), $0.14 (30% open), and $0.15 (30% open).
CONCLUSIONS: PMPM costs did not vary substan-
tially, regardless of different types of formulary access.
Moreover, in line with ﬁndings from local and employer-
based healthcare plans, addition of sildenaﬁl coverage by
this large MCO resulted in lower than expected PMPM
costs.
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OBJECTIVE: The perception persists among employers
and beneﬁt managers that the addition of sildenaﬁl citrate
adds signiﬁcant cost to their prescription plans. A Disease
Therapy Evaluation is a focused analysis of a drug’s per-
formance in a target patient population and provides
healthcare managers with information that may lead to
better decisions for the individual patient as well as the
healthcare organization. The analysis presented here eval-
uates the per member per month (PMPM) cost of silde-
naﬁl without restriction limits on the quantity of tablets
dispensed. METHODS: This retrospective review covered
all sildenaﬁl claims of employees obtained from prescrip-
tion beneﬁt managers. Prescription claims were obtained
for a 6-month interval from December 1999 to May 2000
and imported into an Access database for abstraction of
required data. RESULTS: Data were combined from 4
prescription plans (3 from the Midwest, 1 from the West
Coast) with 361,237 members overall. There were 3477
sildenaﬁl claims in the 6-month period, made by 1493
patients (representing 0.4% of all members). Most of the
prescriptions were for the 50-mg (range for 4 plans,
45%–62%) and 100-mg doses (37%–65%) of sildenaﬁl,
with 1% to 2.5% for the 25-mg dose. On average, 6 to
11 tablets were dispensed at a time, with a range from 1
to 100 tablets. The average cost per prescription varied
from a low end of $50 to a high end of $88; the PMPM
cost ranged from $0.03 to $0.24. CONCLUSIONS: The
actual PMPM cost is markedly lower than the expected
projections, despite the fact that no quantity limits were
imposed. The costs shown here do not take into account
any rebates or other contracting beneﬁts. Thus, employ-
ers may wish to consider the addition of sildenaﬁl to their
beneﬁt package, as it may increase employee satisfaction
without a large impact on the budget.
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